ABVC BIOPHARMA, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $296,000 | $0 | $152,430 | $969,783 | $355,797 |
| Gross profit | — | $508,826 | -$149,607 | $683,368 | $350,711 |
| Operating income | -$7.2M | -$4.7M | -$6.8M | -$15.1M | -$11.7M |
| Operating expenses | $7.2M | $5.2M | $6.6M | $15.8M | $12.1M |
| Cost of revenue | — | $763 | $302,037 | $286,415 | $5,086 |
| Cash from operations | -$3.0M | -$1.8M | -$4.2M | -$7.4M | -$7.6M |
| Capital expenditure | $37.0M | — | $21,201 | $119,692 | $17,503 |
| Free cash flow | -$40.0M | — | -$4.2M | -$7.5M | -$7.6M |
| Share repurchases | — | $7,320 | — | — | — |
| Impairments | — | — | — | $110,125 | $741,390 |
| Total assets | $21.1M | $7.5M | $7.8M | $9.6M | $13.7M |
| Total liabilities | $7.8M | $6.8M | $6.5M | $6.3M | $4.8M |
Shares outstanding 26.0M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.